Related Experiment Video

Updated: Dec 20, 2025

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

3.0K

The case for chronotherapy in Covid-19-induced acute respiratory distress syndrome

Faleh Tamimi1,2, Mohammad Abusamak1, Bindu Akkanti3

  • 1Faculty of Dentistry, McGill University, Montreal, Quebec, Canada.

British Journal of Pharmacology
|May 23, 2020
PubMed

Insights

The study explores how the body's internal clock (circadian rhythm) influences severe COVID-19 lung inflammation. Chronotherapy, or timed treatments, may offer a new way to manage acute respiratory distress syndrome (ARDS) in patients.

Area of Science:

  • Pulmonology
  • Immunology
  • Pharmacology

Background:

  • COVID-19, caused by SARS-CoV-2, has led to a global pandemic with significant mortality.
  • A subset of patients develop severe acute respiratory distress syndrome (ARDS) characterized by a cytokine release storm (CRS).
  • Current anti-inflammatory treatments for ARDS in COVID-19 patients have paradoxically worsened outcomes.

Purpose of the Study:

  • To investigate the hypothesis that the lung and immune system's circadian clock regulates CRS components.
  • To explore the potential of chronotherapy for managing ARDS in COVID-19.

Main Methods:

  • The study hypothesizes a role for circadian rhythms in CRS regulation.
  • It proposes chronotherapy as a potential treatment strategy.

Main Results:

  • The intrinsic circadian clock of the lung and immune system may regulate CRS.
  • This suggests a potential mechanism for chronotherapy in managing ARDS.

Conclusions:

  • Circadian rhythms play a role in the immune response during COVID-19.
  • Chronotherapy presents a promising avenue for managing severe COVID-19 ARDS.

More Related Videos

Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome09:06

Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome

Published on: December 12, 2025

134
Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD04:03

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD

Published on: September 27, 2024

1.2K

Related Concept Videos

Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
365
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
690
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
902
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
655
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
635
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
447